Molly S. Stumacher, M.D. | Hematology/Oncology


Board Certified in 2008

Board Certified in 2007


Bryn Mawr Medical Arts Pavilion
825 Old Lancaster Road
Suite 440
Bryn Mawr, PA 19010

Fax: (610) 525-8561

Education & Training

Medical School
Harvard Medical School, Boston, MA

Department of Medicine, Brigham and Women’s Hospital, Boston, MA

Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA


Bryn Mawr Hospital

Lankenau Hospital

Paoli Hospital

Honors & Awards

Clinical/Dept Titles

Attending Physician

Research Experience

CD40 antibody for the treatment of advanced solid tumors (Phase I study), PI: Robert Vonderheide, M.D., University of Pennsylvania Department of Hematology-Oncology, 2005-2006

CTLA4 antibody in the treatment of advanced breast cancer (Phase I study), PI: Susan Domchek, M.D., University of Pennsylvania Department of Hematology-Oncology, 2005-2006

The use of executive summaries in cancer patients’ consent to clinical trial enrollment (Phase II study), PI: Jane Weeks, M.D. and Steven Joffe, M.D., Dana Farber Cancer Institute, 2003


Vonderheide, RH, Flaherty KT, Khalil M, Stumacher MS, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007 Mar 1;25(7):876-83.

Stumacher, M, Domchek S. Update on chemoprevention in BRCA1and BRCA2 mutation carriers. Breast Cancer Online. 2005 Vol. 8 Issue 9.

Are you ready for our Jumpstart© with OPTIFAST® Program?

Let’s get started! Answer a few basic questions to see if Jumpstart© with OPTIFAST® Program is right for you.

We commit our TIME to you. Can you...commit to once weekly attendance in the evenings?
We commit ACCOUNTABILITY for your needs.Can you...commit to daily written tracking of nutrition and activity?
We commit ENCOURAGEMENT for your goal.Can you...commit to beginning planned physical activity?
This field is for validation purposes and should be left unchanged.